{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:29:06Z","timestamp":1782602946357,"version":"3.54.5"},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T00:00:00Z","timestamp":1210809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background: <\/jats:bold> Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Liver resection or transplantation is curative for a subset of patients with localized disease, but treatments for advanced disease are generally toxic and ineffective. Aberrant expression of the vascular endothelial growth factor (VEGF) has been implicated in the progression of HCC and represents a valid target for anticancer therapy. Bevacizumab, a humanized anti\u2010VEGF monoclonal antibody, is currently being evaluated in the treatment of HCC. In addition, other novel anti\u2010angiogenesis agents are being developed in HCC.<\/jats:p><jats:p><jats:bold>Aim: <\/jats:bold> This study examines the effect of bevacizumab in a newly characterized orthotopic model of the disease using the human HCC cell line, Hep 3B, and provides preclinical evidence that an anti\u2010angiogenic approach holds promise in HCC.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> Administration of bevacizumab 5\u2003mg\/kg intraperitoneal twice a week significantly decreased microvessel density in tumours, decreased human serum \u03b1\u2010fetoprotein measurements and prolonged the time to progression for treatment mice compared with control mice.<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> Our findings suggest that targeting VEGF with bevacizumab may be an effective approach to the treatment of HCC and further study of other novel anti\u2010angiogenic agents in HCC is warranted.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2008.01762.x","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T04:56:42Z","timestamp":1269925002000},"page":"284-290","source":"Crossref","is-referenced-by-count":57,"title":["Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model"],"prefix":"10.1111","volume":"29","author":[{"given":"Richard S.","family":"Finn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn D.","family":"Britten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Amado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Busuttil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00058-3"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401001"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1580"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230309"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1309\/FXNL-QTN1-94FH-AB3A"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.6496"},{"key":"e_1_2_6_8_2","first-page":"1378","article-title":"Survivin expression in hepatocellular carcinoma","volume":"17","author":"Fields AC","year":"2004","journal-title":"correlation with proliferation, prognostic parameters, and outcome"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.504"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1381"},{"key":"e_1_2_6_11_2","first-page":"646","article-title":"Blocking anti\u2010apoptosis as a strategy for cancer chemotherapy","volume":"4","author":"Monks NR","year":"2004","journal-title":"NF-kappB as a target"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.1537"},{"key":"e_1_2_6_13_2","first-page":"2892","article-title":"Hepatocellular carcinoma","volume":"23","author":"Thomas MB","year":"2005","journal-title":"the need for progress"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.20.10589"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1309\/FXNL-QTN1-94FH-AB3A"},{"key":"e_1_2_6_17_2","first-page":"379","article-title":"Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma","volume":"22","author":"Dhar DK","year":"2002","journal-title":"a comparison with angiopoietin\/Tie pathway"},{"key":"e_1_2_6_18_2","first-page":"552","article-title":"Overexpression of VEGF and angiopoietin 2","volume":"6","author":"Moon WS","year":"2003","journal-title":"a key to high vascularity of hepatocellular carcinoma?"},{"key":"e_1_2_6_19_2","first-page":"5339","article-title":"Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma","volume":"14","author":"Poon RT","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_20_2","first-page":"184","article-title":"Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma","volume":"4","author":"Kim SJ","year":"2004","journal-title":"correlations with clinical parameters and survival"},{"key":"e_1_2_6_21_2","first-page":"3121","article-title":"Quantitative correlation of serum level and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma","volume":"63","author":"Poon TP","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_22_2","first-page":"643","article-title":"Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma","volume":"5","author":"Jeng KS","year":"2004","journal-title":"a prospective study"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2003.10.002"},{"key":"e_1_2_6_24_2","first-page":"1077","article-title":"High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma","volume":"5","author":"Poon RT","year":"2004","journal-title":"a prospective study"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","unstructured":"SandlerAB GrayR BrahmerJ et al. Randomized phase II\/III trial of paclitaxel (P) plus carboplatin\u00a9with or without bevacizumab (NSC #704865) in patients with advanced non\u2010squamous non\u2010small cell lung cancer (NSCLCA): an Eastern Cooperative Oncology Group (ECOG) Trial \u2013 E4599. American Society of Clinical Oncology Annual Meeting Abstract LBA4 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.lba4"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","unstructured":"SchwartzJD SchwartzM GoldmanJ et al. Bevacizumab in hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. American Society of Clinical Oncology Annual Meeting Abstract 134 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.4122"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","unstructured":"BrittenCD FinnRS GomesAS et al. A pilot study of IV bevacizumab in hepatocellular carcinoma cancer patients undergoing chemoembolization. American Society of Clinical Oncology Annual Meeting Abstract 4138 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.4138"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.9130"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","unstructured":"ThomasMB ChadhaR IwasakiM et al. The combination of bevacizumab and erlotinib shows significant biologic activity in patients with advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology 2007. ASCO Annual Meeting Proceedings Part 1 Vol 25 No. 18S (June 20 supplement) 2007 p. 4567.","DOI":"10.1200\/jco.2007.25.18_suppl.4567"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3462"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1377"},{"key":"e_1_2_6_33_2","first-page":"2719","article-title":"A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis","volume":"9","author":"Yao X","year":"2003","journal-title":"Clin Can Res"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/362841a0"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104"},{"key":"e_1_2_6_36_2","first-page":"2378","article-title":"Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long\u2010term prognosis in cirrhotic patients","volume":"12","author":"Ono T","year":"2001","journal-title":"metaanalysis of three randomized controlled trials"},{"key":"e_1_2_6_37_2","first-page":"593","article-title":"Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma","volume":"3","author":"Schwartz JD","year":"2002","journal-title":"review of the randomized clinical trials"},{"key":"e_1_2_6_38_2","first-page":"1734","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma","volume":"359","author":"Llovet JM","year":"2002","journal-title":"a randomized controlled trial"},{"key":"e_1_2_6_39_2","first-page":"429","article-title":"Systemic review of randomized trials for unresectable hepatocellular carcinoma","volume":"2","author":"Llovet JM","year":"2003","journal-title":"chemoembolization improves survival"},{"key":"e_1_2_6_40_2","first-page":"1087","article-title":"Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma","volume":"6","author":"Susuzki H","year":"1999","journal-title":"Int J Oncol"},{"key":"e_1_2_6_41_2","first-page":"280","article-title":"Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization","volume":"3","author":"Liao X","year":"2003","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"e_1_2_6_42_2","doi-asserted-by":"crossref","unstructured":"LlovetJ RicciS MazzarferroV et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a Phase III randomized placebo\u2010controlled trial (SHARP trial). Journal of Clinical Oncology 2007. ASCO Annual Meeting Proceedings Part 1 Vol 25 No. 18S (June 20 supplement) 2007 p. LBA1.","DOI":"10.1200\/jco.2007.25.18_suppl.lba1"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.3441"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2008.01762.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2008.01762.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T02:28:15Z","timestamp":1697250495000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2008.01762.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,6]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["10.1111\/j.1478-3231.2008.01762.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01762.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,6]]}}}